MiNK Therapeutics (NASDAQ:INKT - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect MiNK Therapeutics to announce earnings of ($0.50) per share and revenue of $0.88 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.
MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.02). On average, analysts expect MiNK Therapeutics to post ($2.20) EPS for the current fiscal year and ($2.19) EPS for the next fiscal year.
MiNK Therapeutics Stock Performance
Shares of NASDAQ INKT opened at $10.76 on Thursday. The stock has a market cap of $54.88 million, a PE ratio of -4.48 and a beta of 0.49. The business has a fifty day moving average of $11.29 and a two-hundred day moving average of $11.28. MiNK Therapeutics has a 52-week low of $8.48 and a 52-week high of $16.93.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on INKT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Zacks Research cut shares of MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 12th. HC Wainwright initiated coverage on shares of MiNK Therapeutics in a report on Wednesday. They set a "buy" rating and a $38.00 price target for the company. Finally, B. Riley Financial restated a "buy" rating and issued a $50.00 price target (up from $43.00) on shares of MiNK Therapeutics in a research report on Wednesday, October 21st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, MiNK Therapeutics has a consensus rating of "Hold" and an average target price of $44.00.
Read Our Latest Research Report on INKT
Insider Activity
In related news, CEO Jennifer Buell sold 6,938 shares of MiNK Therapeutics stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the transaction, the chief executive officer directly owned 74,195 shares of the company's stock, valued at $783,499.20. The trade was a 8.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is owned by corporate insiders.
About MiNK Therapeutics
(
Get Free Report)
MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company's platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.
MiNK's lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiNK Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.
While MiNK Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.